Wockhardt UK secures £20m funding for global vaccine programme

In a significant move to enhance its global vaccine program, Wockhardt UK, a key healthcare manufacturer, has secured a £20 million funding package from NatWest, orchestrated by RSM UK. This funding marks a pivotal chapter for Wockhardt UK, enabling substantial modernization of its facilities and the rollout of multiple new vaccines.

With a rich history dating back to 1950 and a significant role during the COVID-19 pandemic—producing over 100 million doses of the AstraZeneca vaccine—Wockhardt UK is set to elevate its operations to new heights. The investment will facilitate the acquisition of advanced manufacturing equipment and support Wockhardt’s strategic growth initiatives both domestically and internationally.

Ravi Limaye OBE, Managing Director at Wockhardt UK, expressed enthusiasm about the partnership with RSM UK, highlighting the funding as a catalyst for realizing the company’s facility upgrade plans and continuing to provide high-quality medicines globally. "This investment not only enables us to advance our technology and expand our vaccine portfolio but also solidifies our commitment to global health," stated Limaye.

Legal advisors Eversheds and Hill Dickinson played key roles in finalizing the deal, ensuring a smooth funding process. Ashley Suter of RSM emphasized Wockhardt's crucial role in the pharmaceutical sector and its ongoing contributions to the UK's health sector, particularly in light of the government’s COVID-19 recovery plan.

This investment promises to bolster Wockhardt UK's position as a leader in the pharmaceutical manufacturing industry, driving further innovation and enhancing global healthcare solutions.